A PHASE I, OPEN-LABEL, MULTI-CENTER STUDY OF SAFETY AND DOSE OF FAZ053 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES

Registry ID

CFAZ053X2101

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

NOVARTIS PHARMACEUTICALS CANADA INC

Start date

2021-11-15

Last update

2016-10-06

Conditions

• MALIGNANCIES

Related clinical trials

• A RANDOMIZED PHASE I/II STUDY OF ONIVYDE IN COMBINATION WITH TALAZOPARIB OR TEMOZOLOMIDE IN CHILDREN AND YOUNG ADULTS WITH RECURRENT SOLID MALIGNANCIES AND EWING SARCOMA
• PRIMARY THROMBOPROPHYLAXIS IN PATIENTS WITH MALIGNANCY AND CENTRAL VENOUS CATHETERS: A RANDOMIZED CONTROLLED TRIAL (TRIM-LINE)
• A PHASE IIIB/IV SAFETY TRIAL OF FLAT DOSE NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN PARTICIPANTS WITH ADVANCED MALIGNANCIES

View on source registry